{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:09:28Z","timestamp":1791220168424,"version":"4.1.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>\n                    Pain is an unpleasant experience and effects daily routine negatively. Although there are various drugs, many of them are not entirely successful in relieving pain, since pain modulation is a complex process involving numerous mediators and receptors. Therefore, it is a rational approach to identify the factors involved in the complex process and develop new agents that act on these pain producing mechanisms. In this respect, the involvement of the imidazoline receptors in pain modulation has drawn attention in recent years. In this review, it is aimed to focus on the imidazoline receptors and their ligands which contribute to the pain modulation. It is demonstrated that imidazoline-2 (I\n                    <jats:sub>2<\/jats:sub>\n                    ) receptors are steady new drug targets for analgesics. Even if the mechanism of I\n                    <jats:sub>2<\/jats:sub>\n                    receptor is not well known in the modulation of pain, it is known that it plays a role in tonic and chronic pain but not in acute phasic pain. Moreover, the I\n                    <jats:sub>2<\/jats:sub>\n                    receptor ligands increase the analgesic effects of opioids in both acute and chronic pain and prevent the development of opioid tolerance. So, they are valuable for the chronic pain treatment and also therapeutic coadjuvants in the management of chronic pain with opiate drugs due to the attenuation of opioid tolerance and addiction. Thus, the use of the ligands which bind to the imidazoline receptors is an effective strategy for relieving pain. This educational forum exhibits the role of imidazoline receptors and ligands in pain process by utilizing experimental studies.\n                  <\/jats:p>","DOI":"10.4103\/0253-7613.165196","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T06:44:00Z","timestamp":1442385840000},"page":"472-478","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["The imidazoline receptors and ligands in pain modulation"],"prefix":"10.4103","volume":"47","author":[{"given":"Nurcan","family":"Bektas","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Nemutlu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Arslan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260528","first-page":"209","article-title":"Part III: Pain terms, A current list with definitions and notes on usage","author":"Merskey","year":"1994","journal-title":"Classification of Chronic Pain, IASP Task Force on Taxonomy"},{"key":"R2-20260528","first-page":"507","article-title":"The anatomy and physiology of pain","volume":"27","author":"Steeds","year":"2009","journal-title":"Surgery"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ilar.40.3.111","article-title":"Inflammatory Models of Pain and Hyperalgesia","volume":"40","author":"Ren","year":"1999","journal-title":"ILAR J"},{"key":"R4-20260528","first-page":"07","article-title":"Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment","author":"Baron","year":"2010","journal-title":"Lancet Neurol"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-2999(97)01118-7","article-title":"BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors","volume":"333","author":"Diaz","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.12555","article-title":"Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain","volume":"171","author":"Li","year":"2014","journal-title":"Br J Pharmacol"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.1999.tb09383.x","article-title":"Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand, in rats","volume":"881","author":"Jett","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-33823-9_1","article-title":"Peripheral and central mechanisms of pain generation","volume":"177","author":"Schaible","year":"2007","journal-title":"Handb Exp Pharmacol"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/14728214.2014.915025","article-title":"Emerging drugs for neuropathic pain","volume":"19","author":"Gilron","year":"2014","journal-title":"Expert Opin Emerg Drugs"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2011.02.038","article-title":"Imidazoline I2 receptors: Target for new analgesics?","volume":"658","author":"Li","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0014-2999(75)90235-6","article-title":"Role of the ventral surface of the brain stem in the hypotensive action of clonidine","volume":"34","author":"Bousquet","year":"1975","journal-title":"Eur J Pharmacol"},{"key":"R13-20260528","first-page":"111","article-title":"Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain","volume":"4","author":"Ferrari","year":"2011","journal-title":"J Pain Res"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0968-0896(01)00420-5","article-title":"I(2)-imidazoline binding site affinity of a structurally different type of ligands","volume":"10","author":"Dardonville","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev.pa.36.040196.002455","article-title":"Imidazoline receptors and their endogenous ligands","volume":"36","author":"Regunathan","year":"1996","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10253890802302908","article-title":"Modulation of stress by imidazoline binding sites: Implications for psychiatric disorders","volume":"12","author":"Smith","year":"2009","journal-title":"Stress"},{"key":"R17-20260528","first-page":"866","article-title":"Small Animal Critical Care Medicine","author":"Pypendop","year":"2015"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1476-5381.2012.01894.x","article-title":"Characterization of the hypothermic effects of imidazoline I2 receptor agonists in rats","volume":"166","author":"Thorn","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2015.01.013","article-title":"Discriminative stimulus effects of the imidazoline I2 receptor ligands BU224 and phenyzoline in rats","volume":"749","author":"Qiu","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"R20-20260528","first-page":"55","article-title":"Functional endoscopic sinus surgery under sphenopalatine block or general anaesthesia: Effects on postoperative pain","volume":"14","author":"Aydin","year":"2002","journal-title":"A\u011fr\u0131"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1196\/annals.1304.010","article-title":"Effect of agmatine on acute and mononeuropathic pain","volume":"1009","author":"Aricioglu","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/15563650.2014.898770","article-title":"Significance of the imidazoline receptors in toxicology","volume":"52","author":"Lowry","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1749-6632.1999.tb09337.x","article-title":"Imidazoline binding domains on MAO-B. Localization and accessibility","volume":"881","author":"Raddatz","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(98)01244-9","article-title":"\u2018Seeing through a glass darkly\u2019: Casting light on imidazoline \u2018I\u2019 sites","volume":"19","author":"Eglen","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pnpbp.2012.04.007","article-title":"Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice","volume":"39","author":"Villarinho","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2006.09.021","article-title":"The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes","volume":"552","author":"Bour","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/sj.bjp.0703294","article-title":"Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: A model to detect agonist and antagonist activities at these receptors","volume":"130","author":"S\u00e1nchez-Bl\u00e1zquez","year":"2000","journal-title":"Br J Pharmacol"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.tips.2006.05.004","article-title":"Antidepressants and pain","volume":"27","author":"Mic\u00f3","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/157015909790031201","article-title":"Serotonin-norepinephrine reuptake inhibitors for pain control: Premise and promise","volume":"7","author":"Marks","year":"2009","journal-title":"Curr Neuropharmacol"},{"key":"R32-20260528","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pnpbp.2013.02.005","article-title":"The antinociceptive effect of reversible monoamine oxidase-A inhibitors in a mouse neuropathic pain model","volume":"44","author":"Villarinho","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R33-20260528","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/pr.55.4.4","article-title":"International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology","volume":"55","author":"Neubig","year":"2003","journal-title":"Pharmacol Rev"},{"key":"R34-20260528","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0165-6147(02)02036-9","article-title":"The ligand paradox between affinity and efficacy: Can you be there and not make a difference?","volume":"23","author":"Kenakin","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"R36-20260528","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1476-5381.1995.tb16656.x","article-title":"RS-45041-190: A selective, high-affinity ligand for I2 imidazoline receptors","volume":"116","author":"Brown","year":"1995","journal-title":"Br J Pharmacol"},{"key":"R37-20260528","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/sj.bjp.0701214","article-title":"Inhibition of monoamine oxidase A and B activities by imidazol(ine)\/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver","volume":"121","author":"Ozaita","year":"1997","journal-title":"Br J Pharmacol"},{"key":"R38-20260528","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjp.0706019","article-title":"Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway","volume":"143","author":"Macinnes","year":"2004","journal-title":"Br J Pharmacol"},{"key":"R40-20260528","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.bjp.0704153","article-title":"Biological significance of agmatine, an endogenous ligand at imidazoline binding sites","volume":"133","author":"Raasch","year":"2001","journal-title":"Br J Pharmacol"},{"key":"R41-20260528","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2010.10.090","article-title":"Determination of a(2)-adrenoceptor and imidazoline receptor involvement in augmentation of morphine and oxycodone analgesia by agmatine and BMS182874","volume":"651","author":"Bhalla","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R42-20260528","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0893-133X(00)00245-1","article-title":"Agmatine potentiates the analgesic effect of morphine by an \u03b12-adrenoceptor-mediated mechanism in mice","volume":"25","author":"Yesilyurt","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R43-20260528","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1196\/annals.1304.011","article-title":"Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception","volume":"1009","author":"Roerig","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R44-20260528","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainres.2007.04.050","article-title":"Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice","volume":"1159","author":"Paszcuk","year":"2007","journal-title":"Brain Res"},{"key":"R45-20260528","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2006.09.031","article-title":"Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects","volume":"553","author":"Gentili","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"R46-20260528","first-page":"151","article-title":"CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats","volume":"5","author":"Meregalli","year":"2012","journal-title":"J Pain Res"},{"key":"R47-20260528","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1111\/bph.12728","article-title":"Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats","volume":"171","author":"Lanza","year":"2014","journal-title":"Br J Pharmacol"},{"key":"R48-20260528","doi-asserted-by":"crossref","first-page":"A358","DOI":"10.1016\/j.joca.2015.02.660","article-title":"Analgesic efficacy of CR4056, a novel I2-imidazoline receptor ligand, in the rat monosodium iodoacetate model of osteoarthritic pain","volume":"23","author":"Caselli","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"R50-20260528","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/WNR.0b013e32834e7db3","article-title":"Effects of imidazoline I2 receptor ligands on acute nociception in rats","volume":"23","author":"Sampson","year":"2012","journal-title":"Neuroreport"},{"key":"R51-20260528","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejphar.2011.09.173","article-title":"Effects of imidazoline I2 receptor ligands on morphine- and tramadol-induced antinociception in rats","volume":"670","author":"Thorn","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R52-20260528","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1476-5381.1984.tb10753.x","article-title":"The relative contribution of affinity and efficacy to agonist activity: Organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptors","volume":"81","author":"Kenakin","year":"1984","journal-title":"Br J Pharmacol"},{"key":"R53-20260528","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.pbb.2012.10.007","article-title":"Potentiation of oxycodone antinociception in mice by agmatine and BMS182874 via an imidazoline I2 receptor-mediated mechanism","volume":"103","author":"Bhalla","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"R54-20260528","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2999(95)00214-6","article-title":"LSL 60101, a selective ligand for imidazoline I2 receptors, on glial fibrillary acidic protein concentration","volume":"280","author":"Alemany","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"R55-20260528","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1749-6632.1999.tb09351.x","article-title":"Binding of tracizolines to the imidazoline receptor. Role of lipophilicity in quantitative structure-activity relationship models","volume":"881","author":"Pigini","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"R56-20260528","first-page":"232","article-title":"Effects of agmatine on tolerance to and substance dependence on morphine in mice","volume":"20","author":"Li","year":"1999","journal-title":"Zhongguo Yao Li Xue Bao"},{"issue":"478","key":"R57-20260528","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2003.08.048","article-title":"Modulation by a-difluoromethyl-ornithine and aminoguanidine of pain threshold, morphine analgesia and tolerance","volume":"8","author":"Lu","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"R58-20260528","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bjp.0702031","article-title":"Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands","volume":"125","author":"Boronat","year":"1998","journal-title":"Br J Pharmacol"},{"key":"R59-20260528","first-page":"1011","article-title":"Influence of idazoxan on analgesia, tolerance, and physical dependence of morphine in mice and rats in vivo","volume":"21","author":"Su","year":"2000","journal-title":"Acta Pharmacol Sin"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363791-201547050-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:19:20Z","timestamp":1787843960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363791-201547050-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0253-7613.165196","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"2015-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-08-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}